Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease
Tóm tắt
Pulmonary hypertension is prevalent in adult patients with sickle cell disease and is strongly associated with early mortality and markers of hemolysis, in particular, serum lactate dehydrogenase (LDH). Intravascular hemolysis leads to impaired bioavailability of nitric oxide (NO), mediated by NO scavenging by plasma oxyhemoglobin and by arginine degradation by plasma arginase. We hypothesized that serum LDH may represent a convenient biomarker of intravascular hemolysis and NO bioavailability, characterizing a clinical subphenotype of hemolysis-associated vasculopathy. In a cohort of 213 patients with sickle cell disease, we found statistically significant associations of steady-state LDH with low levels of hemoglobin and haptoglobin and high levels of reticulocytes, bilirubin, plasma hemoglobin, aspartate aminotransferase, arginase, and soluble adhesion molecules. LDH isoenzyme fractionation confirmed predominance of LD1 and LD2, the principal isoforms within erythrocytes. In a subgroup, LDH levels closely correlated with plasma cell-free hemoglobin, accelerated NO consumption by plasma, and impaired vasodilatory responses to an NO donor. Remarkably, this simple biomarker was associated with a clinical subphenotype of pulmonary hypertension, leg ulceration, priapism, and risk of death in patients with sickle cell disease. We propose that LDH elevation identifies patients with a syndrome of hemolysis-associated NO resistance, endothelial dysfunction, and end-organ vasculopathy.
Tài liệu tham khảo
Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med.2004;350: 886-895.
Kato GJ, Martyr S, Blackwelder WC, et al. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br J Haematol.2005;130: 943-953.
Brown MD, Wick TM, Eckman JR. Activation of vascular endothelial cell adhesion molecule expression by sickle blood cells. Pediatr Pathol Mol Med2001;20: 47-72.
Duits AJ, Pieters RC, Saleh AW, et al. Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol.1996;81: 96-98.
Duits AJ, Rojer RA, van Endt T, et al. Erythropoiesis and serum sVCAM-1 levels in adults with sickle cell disease. Ann Hematol.2003;82: 171-174.
Saleh AW, Duits AJ, Gerbers A, de Vries C, Hillen HF. Cytokines and soluble adhesion molecules in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol.1998;100: 26-31.
Saleh AW, Hillen HF, Duits AJ. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol.1999;102: 31-37.
Schnog JB, Rojer RA, Mac Gillavry MR, et al. Steady-state sVCAM-1 serum levels in adults with sickle cell disease. Ann Hematol.2003;82: 109-113.
Shiu YT, Udden MM, McIntire LV. Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood.2000;95: 3232-3241.
Solovey AA, Solovey AN, Harkness J, Hebbel RP. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood.2001;97: 1937-1941.
Tabbara IA. Hemolytic anemias. Diagnosis and management. Med Clin North Am.1992;76: 649-668.
Bensinger TA, Gillette PN. Hemolysis in sickle cell disease. Arch Intern Med.1974;133: 624-631.
Naumann HN, Diggs LW, Barreras L, Williams BJ. Plasma hemoglobin and hemoglobin fractions in sickle cell crisis. Am J Clin Pathol.1971;56: 137-147.
Neely CL, Wajima T, Kraus AP, Diggs LW, Barreras L. Lactic acid dehydrogenase activity and plasma hemoglobin elevations in sickle cell disease. Am J Clin Pathol.1969;52: 167-169.
Ballas SK, Marcolina MJ. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion.2006;46: 105-110.
Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med.2002;8: 1383-1389.
Gladwin MT, Schechter AN, Ognibene FP, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation.2003;107: 271-278.
Morris CR, Morris SM, Jr., Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Crit Care Respir Med.2003;168: 63-69.
Schnog JJ, Jager EH, van der Dijs FP, et al. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Ann Hematol.2004;83: 371-375.
Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA.2005;294: 81-90.
Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A.2001;98: 15215-15220.
Wood KC, Hebbel RP, Granger DN. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J2005;19: 989-991.
Aslan M, Freeman BA. Oxidant-mediated impairment of nitric oxide signaling in sickle cell disease—mechanisms and consequences. Cell Mol Biol (Noisy-le-grand)2004;50: 95-105.
Aslan M, Ryan TM, Townes TM, et al. Nitric oxide-dependent generation of reactive species in sickle cell disease. Actin tyrosine induces defective cytoskeletal polymerization. J Biol Chem.2003;278: 4194-4204.
Kaul DK, Liu XD, Fabry ME, Nagel RL. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am J Physiol Heart Circ Physiol.2000;278: H1799-H1806.
Belhassen L, Pelle G, Sediame S, et al. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood.2001;97: 1584-1589.
Eberhardt RT, McMahon L, Duffy SJ, et al. Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. Am J Hematol.2003;74: 104-111.
Nath KA, Shah V, Haggard JJ, et al. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol.2000;279: R1949-R1955.
Kaul DK, Liu XD, Chang HY, Nagel RL, Fabry ME. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest2004;114: 1136-1145.
Minneci PC, Deans KJ, Zhi H, et al. A novel mechanism of disease: hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest.2005;115: 3409-3417.
Kopperschlager G, Kirchberger J. Methods for the separation of lactate dehydrogenases and clinical significance of the enzyme. J Chromatogr B Biomed Appl.1996;684: 25-49.
Adhikary PK, Hara S, Dwivedi C, et al. Vasoocclusive crisis episodes in sickle cell disease. J Med.1986;17: 227-240.
Sonntag O. Haemolysis as an interference factor in clinical chemistry. J Clin Chem Clin Biochem.1986;24: 127-139.
Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA.2005;293: 1653-1662.
Pawloski JR, Hess DT, Stamler JS. Impaired vasodilation by red blood cells in sickle cell disease. Proc Natl Acad Sci U S A.2005;102: 2531-2536.
Ergul S, Brunson CY, Hutchinson J, et al. Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1-mediated vasoconstriction. Am J Hematol.2004;76: 245-251.
Rybicki AC, Fabry ME, Does MD, Kaul DK, Nagel RL. Differential gene expression in the kidney of sickle cell transgenic mice: upregulated genes. Blood Cells Mol Dis.2003;31: 370-380.
Lee SK, Kim JH, Yang WS, et al. Exogenous nitric oxide inhibits VCAM-1 expression in human peritoneal mesothelial cells. Role of cyclic GMP and NF-kappaB. Nephron.2002;90: 447-454.
Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci U S A.1996;93: 9114-9119.
Cartwright JE, Whitley GS, Johnstone AP. Endothelial cell adhesion molecule expression and lymphocyte adhesion to endothelial cells: effect of nitric oxide. Exp Cell Res.1997;235: 431-434.
Space SL, Lane PA, Pickett CK, Weil JV. Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium. Am J Hematol.2000;63: 200-204.
De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest.1995;96: 60-68.
Gurkan E, Tanriverdi K, Baslamisli F. Clinical relevance of vascular endothelial growth factor levels in sickle cell disease. Ann Hematol.2005;84: 71-75.
Setty BN, Stuart MJ, Dampier C, Brodecki D, Allen JL. Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet.2003;362: 1450-1455.
Ballas SK. Sickle cell anemia with few painful crises is characterized by decreased red cell deformability and increased number of dense cells. Am J Hematol.1991;36: 122-130.
Alexander N, Higgs D, Dover G, Serjeant GR. Are there clinical phenotypes of homozygous sickle cell disease? Br J Haematol.2004;126: 606-611.
Dore F, Bonfigli S, Pardini S, Pirozzi F, Longinotti M. Priapism in thalassemia intermedia [letter]. Haematologica.1991;76: 523.
Stevens DM, Shupack JL, Javid J, Silber R. Ulcers of the leg in thalassemia. Arch Dermatol.1977;113: 1558-1560.
Gimmon Z, Wexler MR, Rachmilewitz EA. Juvenile leg ulceration in beta-thalassemia major and intermedia. Plast Reconstr Surg.1982;69: 320-325.
Macchia P, Massei F, Nardi M, et al. Thalassemia intermedia and recurrent priapism following splenectomy. Haematologica.1990;75: 486-487.
Rao KR, Patel AR. Priapism and thalassaemia intermedia [letter]. Br J Surg.1986;73: 1048.
Jackson N, Franklin IM, Hughes MA. Recurrent priapism following splenectomy for thalassaemia intermedia. Br J Surg.1986;73: 678.
Atichartakarn V, Likittanasombat K, Chuncharunee S, et al. Pulmonary arterial hypertension in previously splenectomized patients with betathalassemic disorders. Int J Hematol.2003;78: 139-145.
Derchi G, Fonti A, Forni GL, et al. Pulmonary hypertension in patients with thalassemia major [letter]. Am Heart J.1999;138: 384.
Verresen D, De Backer W, Van Meerbeeck J, et al. Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship? Eur Respir J1991;4: 629-631.
Hayag-Barin JE, Smith RE, Tucker FC Jr. Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: a case report and review of the literature. Am J Hematol.1998;57: 82-84.
Jardine DL, Laing AD. Delayed pulmonary hypertension following splenectomy for congenital spherocytosis. Intern Med J.2004;34: 214-216.
Giraldi S, Abbage KT, Marinoni LP, et al. Leg ulcer in hereditary spherocytosis. Pediatr Dermatol.2003;20: 427-428.
Lawrence P, Aronson I, Saxe N, Jacobs P. Leg ulcers in hereditary spherocytosis. Clin Exp Dermatol.1991;16: 28-30.
Goulding FJ. Priapism caused by glucose phosphate isomerase deficiency. J Urol.1976;116: 819-820.
Thuret I, Bardakdjian J, Badens C, et al. Priapism following splenectomy in an unstable hemoglobin: hemoglobin Olmsted beta 141 (H19) Leu→Arg. Am J Hematol.1996;51: 133-136.
Edney MT, Schned AR, Cendron M, Chaffee S, Ellsworth PI. Priapism in a 15-year-old boy with congenital dyserythropoietic anemia type II (hereditary erythroblastic multinuclearity with positive acidified serum lysis test). J Urol.2002;167: 309-310.
Christakis J, Vavatsi N, Hassapopoulou H, et al. Comparison of homozygous sickle cell disease in northern Greece and Jamaica. Lancet.1990;335: 637-640.
Kar BC, Satapathy RK, Kulozik AE, et al. Sickle cell disease in Orissa State, India. Lancet.1986;2: 1198-1201.
Dash BP, Kar BC. Priapism is rare in sickle cell disease in India. J Assoc Physicians India.2000;48: 255.
Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis associated priapism in sickle cell disease. Blood.2005;106: 3264-3267.
Homi J, Levee L, Higgs D, Thomas P, Serjeant G. Pulse oximetry in a cohort study of sickle cell disease. Clin Lab Haematol.1997;19: 17-22.
Rackoff WR, Kunkel N, Silber JH, Asakura T, Ohene-Frempong K. Pulse oximetry and factors associated with hemoglobin oxygen desaturation in children with sickle cell disease. Blood.1993;81: 3422-3427.
Quinn CT, Ahmad N. Clinical correlates of steady-state oxyhaemoglobin desaturation in children who have sickle cell disease. Br J Haematol.2005;131: 129-134.